The Finn Sawyer Access to Cancer Testing Act aims to significantly improve access to advanced cancer diagnostics by expanding coverage under federal health programs. It mandates that Medicare will cover specific cancer diagnostic and laboratory tests, including microarray analysis, DNA sequencing, RNA sequencing, and whole-exome sequencing, along with their interpretation, for individuals diagnosed with cancer. These tests will be covered upon diagnosis, recurrence, and as needed for treatment planning or monitoring, with the Medicare deductible waived. Furthermore, the bill requires Medicaid and the Children's Health Insurance Program (CHIP) to include these cancer diagnostic and laboratory tests as covered medical assistance, with an effective date of January 1, 2027. This ensures broader access to these critical diagnostic tools across different populations. States requiring legislative changes for Medicaid compliance are granted an exemption period. Beyond coverage, the legislation directs the Secretary of Health and Human Services, in coordination with the National Human Genome Research Institute, to establish an education and awareness program . This program will inform physicians and the general public about genomic testing, its applications, and the vital role of genetic counselors. It also emphasizes integrating education and training on molecular diagnostics for cancer into graduate and continuing medical education, particularly for oncology specialists.